Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer

被引:0
|
作者
Xu, T [1 ]
Wang, XF [1 ]
Hou, SK [1 ]
Zhu, JC [1 ]
Zhang, XD [1 ]
Huang, XB [1 ]
机构
[1] Peking Univ, People Hosp, Dept Urol, Beijing 100044, Peoples R China
关键词
prostate cancer; androgens; arteriosclerosis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To analyze the effect of castration on risk factors for arteriosclerosis of patients with prostate cancer. Methods Thirty patients with primary regional prostate adenocarcinoma limited to the prostate theca were selected in this study. Serum levels of testosterone (T), free testosterone ( FT), dehydroepiandrosterone (DHEA), sex hormone-binding globulin (SHBG), prostatic specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apoprotein alpha(1) (APOalpha(1)) and apoprotein beta (APObeta), insulin, plasma fibrinopeptide A ( FPA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen were determined just prior to, 1 week and 1, 4 and 8 months after castration. Results T, FT and PSA decreased significantly 1 week after castration (21.12 +/- 15.11 ng/ml vs 383.9 +/- 62.6 ng/ml, P < 0.001; 4.08 +/- 3.29 pmol/L vs 34.11 +/- 11.59 pmol/L, P < 0.001; 14.34 +/- 7.77 ng/ml vs 23.51 +/- 6.57 ng/ml, P = 0.001, respectively) and continued to decrease until reaching their lowest levels 8 months after castration. DHEA and SHBG did not undergo any changes. TG, fasting insulin and glucose, 2-hour insulin and glucose levels were significantly elevated 1 month after castration (1.84 +/- 0.61 mmol/L vs 1.30 +/- 0.40 mmol/L, P < 0.05; 18.16 +/- 5.57 mU/L vs 9.47 +/- 3.81 mU/L, P < 0.05; 4.77 +/- 0.66 mmol/L vs 3.92 +/- 0.34 mmol/L, P < 0. 05; 65.52 +/- 14.78 mU/L vs 36.94 +/- 17.12 mU/L, P < 0.01; 6.98 +/- 0.79 mmol/L vs 6.01 +/- 0.23 mmol/L, P = 0.001, respectively). TC, LDL-C, FPA and PAI-1 levels were elevated 4 months after castration (6.56 +/- 0.99 mmol/L vs; 5.29 +/- 0.75 mmol/L, P < 0.01; 4.09 +/- 0.86 mmol/L vs 3.04 +/- 0.15 mmol/L, P < 0.01; 3.39 +/- 1.67 nmol/L vs 1.48 +/- 0.50 nmol/L, P < 0. 01; 27.02 +/- 5.98 ng/ml vs 21.78 +/- 3.16 ng/ml, P < 0. 05, respectively), continuing to increase after that point. Insulin sensitive index (ISI) decreased significantly 1 month after surgery (-4.42 +/- 0.36 vs - 3.50 +/- 0.39, P < 0.001), and continued to decrease from that point forward. HDL-C, APOal, APOP and fibrinogen remained at pre-operative levels. There was a negative linear correlation between FT and TG, TC, LDL-C, PAI-1, FPA, fasting insulin and glucose, 2-hour insulin and glucose ( r = - 0. 311, - 0.384, - 0.385, - 0.339, - 0.353, - 0.381, - 0.303, - 0.460 and - 0. 395, respectively; P < 0.05). A similar phenomenon occurred with T ( r = - 0.308, - 0.309, - 0.356, - 0. 320, - 0.430, - 0.453, - 0.435, - 0.483 and - 0. 512, respectively; P &LT; 0.05). T and FT were positively associated with ISI ( r = 0. 555 and 0. 501; P &LT; 0.001). Conclusions At 8 months follow-up of the study subjects, we found that lower androgen levels have adverse effects on lipid metabolism, coagulative function and insulin sensitivity, related to arteriosclerosis in men.
引用
收藏
页码:1336 / 1340
页数:5
相关论文
共 50 条
  • [21] Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel
    Kosaka, Takeo
    Hongo, Hiroshi
    Mizuno, Ryuichi
    Oya, Mototsugu
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 683 - 688
  • [22] Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
    Shimpei Yamashita
    Yasuo Kohjimoto
    Takashi Iguchi
    Hiroyuki Koike
    Hiroki Kusumoto
    Akinori Iba
    Kazuro Kikkawa
    Yoshiki Kodama
    Nagahide Matsumura
    Isao Hara
    BMC Urology, 16
  • [23] Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
    Yamashita, Shimpei
    Kohjimoto, Yasuo
    Iguchi, Takashi
    Koike, Hiroyuki
    Kusumoto, Hiroki
    Iba, Akinori
    Kikkawa, Kazuro
    Kodama, Yoshiki
    Matsumura, Nagahide
    Hara, Isao
    BMC UROLOGY, 2016, 16
  • [24] Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer.
    Garje, Rohan
    Chennamadhavuni, Adithya
    Mott, Sarah L.
    Chambers, Isaac Matthew
    Gellhaus, Paul
    Zakharia, Yousef
    Brown, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer
    Noldus, J
    Ferrari, M
    Prestigiacomo, A
    Stamey, TA
    UROLOGY, 1996, 47 (05) : 713 - 718
  • [26] Surgical treatment of patients with prostate cancer at high risk of progression
    Nyushko, K. M.
    Alekseev, B. Ya.
    Krasheninnikov, A. A.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2014, 10 (02): : 38 - 45
  • [27] Predictive factors for the efficacy of abiraterone acetate for patients with castration-resistant prostate cancer
    Tokura, Yuumi
    Abe, Hideyuki
    Nishihara, Daisaku
    Mizuno, Tomoya
    Nukui, Akinori
    Kobayashi, Minoru
    Toyoshima, Toyoaki
    Arai, Gaku
    Yashi, Masahiro
    Okada, Hiroshi
    Kamai, Takao
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 456 - 456
  • [28] Treatment for castration-resistant prostate cancer and drug interaction risk in polymedicated patients
    Juarez Soto, A.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (10): : 641 - 643
  • [29] Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study
    Friedemann Honecker
    Ulrich Wedding
    Gerd Kallischnigg
    Axel Schroeder
    Jörg Klier
    Thomas Frangenheim
    Lothar Weißbach
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 571 - 577
  • [30] Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study
    Honecker, Friedemann
    Wedding, Ulrich
    Kallischnigg, Gerd
    Schroeder, Axel
    Klier, Joerg
    Frangenheim, Thomas
    Weissbach, Lothar
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (03) : 571 - 577